Amyloid_cardiomyopathy

Amyloid cardiomyopathy

Amyloid cardiomyopathy

Medical condition

Amyloid cardiomyopathy (stiff heart syndrome)[5] is a condition resulting in the death of part of the myocardium (heart muscle). It is associated with the systemic production and release of many amyloidogenic proteins, especially immunoglobulin light chain or transthyretin (TTR).[6] It can be characterized by the extracellular deposition of amyloids, foldable proteins that stick together to build fibrils in the heart.[7] The amyloid can be seen under polarized light in congo red stained biopsy.[citation needed]

Quick Facts Specialty, Symptoms ...

Symptoms

Amyloid cardiomyopathy is associated with a number of symptoms:

Pathophysiology

Amyloid proteins are deposited in the myocardium.[2] This limits ventricular filling during diastole, which increases end-diastolic volume.[2] This can lead to a variety of cardiac issues, such as congestive heart failure, atrial arrythmia, ventricular arrythmia, and blocks to cardiac nervous conduction.[2]

Diagnosis

Diagnosis is often delayed, because its symptoms are non-specific.[4]

Electrocardiography can be used to identify low voltage and patterns similar to those of a heart attack.[3]

Cardiac MRI can be used to distinguish it from hypertensive heart disease.[1][3] This shows a thicker interventricular septum.[3]

Treatment

Chemotherapy can treat amyloidosis if it is related to immunoglobulins.[4] Liver transplant can treat amyloidosis if it is related to familial transthyretin.[4]

Prognosis

Outcomes for amyloid cardiomyopathy are generally very poor, with fewer than 10% of patients surviving more than 5 years.[2] Without treatment, few patients survive more than 6 months.[2]

Epidemiology

In developed countries, amyloid cardiomyopathy is estimated to be involved in 0.1% of deaths.[2]

References

  1. [1]
    Steingart, Richard M.; Chen, Carol; Liu, Jennifer (2016-01-01), Herrmann, Joerg (ed.), "Chapter 7 - Subtypes of Cancer Involving the Heart", Clinical Cardio-Oncology, Elsevier, pp. 121–131, doi:10.1016/b978-0-323-44227-5.00007-7, ISBN 978-0-323-44227-5, retrieved 2020-11-27
  2. [2]
    Gillespie, Hamilton S.; Benjamin, Ivor J. (2012-01-01), Hill, Joseph A.; Olson, Eric N. (eds.), "Chapter 43 - Infiltrative and Protein Misfolding Myocardial Diseases", Muscle, Boston/Waltham: Academic Press, pp. 625–637, doi:10.1016/b978-0-12-381510-1.00043-0, ISBN 978-0-12-381510-1, retrieved 2020-11-27
  3. [3]
    Benson, Merrill D. (2013-01-01), Rimoin, David; Pyeritz, Reed; Korf, Bruce (eds.), "Chapter 79 - Amyloidosis and Other Protein Deposition Diseases", Emery and Rimoin's Principles and Practice of Medical Genetics, Oxford: Academic Press, pp. 1–18, doi:10.1016/b978-0-12-383834-6.00083-5, ISBN 978-0-12-383834-6, retrieved 2020-11-27
  4. [4]
    Sher, T.; Gertz, M. A. (2018-01-01), "Amyloid Cardiomyopathy", in Vasan, Ramachandran S.; Sawyer, Douglas B. (eds.), Encyclopedia of Cardiovascular Research and Medicine, Oxford: Elsevier, pp. 66–79, doi:10.1016/b978-0-12-809657-4.11051-8, ISBN 978-0-12-805154-2, retrieved 2020-11-27
  5. [5]
    "Cardiac amyloidosis: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2017-12-01.
  6. [6]
    Liao, Ronglih; Ward, Jennifer E. (2017-06-09). "Amyloid Cardiomyopathy: Disease on the Rise". Circulation Research. 120 (12): 1865–1867. doi:10.1161/CIRCRESAHA.117.310643. ISSN 0009-7330. PMC 5584551. PMID 28596171.
  7. [7]
    Falk, Rodney H.; Dubrey, Simon W. (2010-01-01). "Amyloid Heart Disease". Progress in Cardiovascular Diseases. Unusual Cardiomyopathies. 52 (4): 347–361. doi:10.1016/j.pcad.2009.11.007. PMID 20109604.
Share this article:

This article uses material from the Wikipedia article Amyloid_cardiomyopathy, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.